Jeil PharmaceuticalLtd Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Jeil PharmaceuticalLtd's earnings have been declining at an average annual rate of -16.9%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 0.6% per year.
Anahtar bilgiler
-16.9%
Kazanç büyüme oranı
-17.0%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 11.3% |
| Gelir büyüme oranı | 0.6% |
| Özkaynak getirisi | -20.3% |
| Net Marj | -5.1% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Gelir ve Gider Dağılımı
Jeil PharmaceuticalLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 700,468 | -35,739 | 130,976 | 42,957 |
| 31 Mar 24 | 705,759 | -10,576 | 130,870 | 46,668 |
| 31 Dec 23 | 726,394 | 5,005 | 129,129 | 45,727 |
| 30 Sep 23 | 718,168 | 3,638 | 128,045 | 42,828 |
| 30 Jun 23 | 717,079 | 3,944 | 127,832 | 40,866 |
| 31 Mar 23 | 733,281 | 3,533 | 128,061 | 39,991 |
| 31 Dec 22 | 722,230 | -13,091 | 128,527 | 41,147 |
| 30 Sep 22 | 723,809 | -20,556 | 131,103 | 40,957 |
| 30 Jun 22 | 729,397 | -17,107 | 128,010 | 44,838 |
| 31 Mar 22 | 710,234 | -15,079 | 128,826 | 41,084 |
| 31 Dec 21 | 700,693 | -12,473 | 126,989 | 38,974 |
| 30 Sep 21 | 700,569 | -1,128 | 124,225 | 36,720 |
| 30 Jun 21 | 692,115 | -343 | 125,625 | 31,218 |
| 31 Mar 21 | 690,946 | 1,781 | 121,776 | 28,401 |
| 31 Dec 20 | 691,325 | 6,916 | 119,493 | 24,270 |
| 30 Sep 20 | 685,674 | -6,977 | 117,848 | 24,844 |
| 30 Jun 20 | 679,369 | -6,303 | 120,419 | 22,613 |
| 31 Dec 19 | 671,407 | -10,239 | 121,210 | 22,114 |
Kaliteli Kazançlar: A271980 is currently unprofitable.
Büyüyen Kar Marjı: A271980 is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: A271980 is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Büyüme Hızlandırma: Unable to compare A271980's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: A271980 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
Özkaynak Getirisi
Yüksek ROE: A271980 has a negative Return on Equity (-20.34%), as it is currently unprofitable.